Current Report Filing (8-k)
August 06 2020 - 05:16PM
Edgar (US Regulatory)
false 0001466301 0001466301 2020-08-06
2020-08-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 6,
2020
Clovis Oncology, Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-35347 |
|
90-0475355 |
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
5500 Flatiron Parkway, Suite 100
Boulder, Colorado
|
|
80301 |
(Address of principal
executive offices)
|
|
(Zip Code) |
Registrant’s telephone number, including area code: (303)
625-5000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock par Value $0.001 per
Share |
|
CLVS |
|
The NASDAQ Global Select
Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act ☐
Item 2.02 |
Results of Operations and Financial Condition
|
On August 6, 2020, Clovis Oncology, Inc. (the “Company”)
issued a press release announcing its financial results for the
quarter ended June 30, 2020. A copy of the press release is
attached as Exhibit 99.1 and is incorporated herein by
reference.
The information in this Item 2.02 of Form 8-K and the information incorporated by
reference herein, including Exhibit 99.1 attached hereto, shall not
be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise
subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of
1933 or the Exchange Act, except as expressly set forth by specific
reference in such filing.
Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits.
Number and Description
- 2 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CLOVIS ONCOLOGY, INC. |
|
|
|
|
August 6, 2020 |
|
|
|
By: |
|
/s/ Paul Gross
|
|
|
|
|
Name: |
|
Paul Gross |
|
|
|
|
Title: |
|
Executive Vice President and
General Counsel |
- 3 -
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Dec 2020 to Jan 2021
Clovis Oncology (NASDAQ:CLVS)
Historical Stock Chart
From Jan 2020 to Jan 2021